


Novel Approaches for the Delivery of Viable and Healthy Cells for Cell Therapy Treatment

Novo Nordisk is seeking **novel cell delivery solutions to improve cell therapy treatments** in humans. Specifically, the team is interested in device, biomaterial and formulation approaches to **improve efficacy in Type 1 Diabetes, Chronic Heart failure and Parkinson's Disease**.



Approaches of Interest:

- Biomaterial or formulation approaches for the preparation and administration of viable and healthy cells at point of delivery (i.e. recovery from cryopreservation, resuspension and delivery).
 - Key challenges include limiting cell stress (shear, temperature and pH) and exposure to deleterious agents, as well as promoting angiogenesis.
 - Methods to prevent cell sedimentation and achieve uniform dosage are of particular interest.
- Smart biomaterial approaches to direct cell fate or allow specific alignment/positioning of cells during/following delivery to the target area (E.g. cell sheets).
- Cell injection/implantation devices for accurate delivery of cells into the target site. Methods which manage inflammation and mitigate fibrosis are of particular interest.

Clinical Indications of Interest:

- Type 1 Diabetes with focus on delivery of Beta cells for bio-artificial pancreas approaches
- Delivery of cardiac cells for treatment of Chronic Heart Failure
- Delivery of neuron cells to the mid-brain for treatment of Parkinson's Disease

Developmental Stages of Interest:

Opportunities should have a demonstrated proof of concept (PoC) data, or a clear and defined route to achieve PoC within a 6-month time frame. This information can be outlined using the submission form below.

Submission Information and Opportunity for Collaboration

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Submissions should include details of achieved PoC or, alternatively, a proposal to achieve PoC should be outlined using this **submission form**. In submitting to this campaign, you confirm that your submission contains only non-confidential information, and that you agree to the Competition terms outlined in the **submission form**.

Novo Nordisk is open to partnering and collaborations to support research towards a proof of concept work, or the appropriate next steps. Funding and support up to \$75,000 may be made available to promising applications and will be judged by the Novo Nordisk team on a case-by-case basis.

Opportunities sought

-  Biotech assets
-  Spinout companies
-  Research projects
-  Centres of excellence
-  Academics and expertise
-  Technologies

Submissions

Please submit relevant, non-confidential opportunities to **Karla Schramm** at kschramm@usf.edu

Deadline: **12th August 2024 - 4:59 pm GMT**

Have any questions?

Contact **Karla Schramm** at kschramm@usf.edu